18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Solid tumours are less oxygenated than normal tissues. Consequently, cancer cells acquire to be adapted to a hypoxic environment. The poor oxygenation of solid tumours is also a major indicator of an adverse cancer prognosis and leads to resistance to conventional anticancer treatments. We previously showed the involvement of Che-1/AATF (Che-1) in cancer cell survival under stress conditions. Herein we hypothesized that Che-1 plays a role in the response of cancer cells to hypoxia.

          Methods

          The human colon adenocarcinoma HCT116 and HT29 cell lines undepleted or depleted for Che-1 expression by siRNA, were treated under normoxic and hypoxic conditions to perform studies regarding the role of this protein in metabolic adaptation and cell proliferation. Che-1 expression was detected using western blot assays; cell metabolism was assessed by NMR spectroscopy and functional assays. Additional molecular studies were performed by RNA seq, qRT-PCR and ChIP analyses.

          Results

          Here we report that Che-1 expression is required for the adaptation of cells to hypoxia, playing an important role in metabolic modulation. Indeed, Che-1 depletion impacted on HIF-1α stabilization, thus downregulating the expression of several genes involved in the response to hypoxia and affecting glucose metabolism.

          Conclusions

          We show that Che-1 a novel player in the regulation of HIF-1α in response to hypoxia. Notably, we found that Che-1 is required for SIAH-2 expression, a member of E3 ubiquitin ligase family that is involved in the degradation of the hydroxylase PHD3, the master regulator of HIF-1α stability.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s13046-017-0497-1) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          On the origin of cancer cells.

          O WARBURG (1956)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

            HIF (hypoxia-inducible factor) is a transcription factor that plays a pivotal role in cellular adaptation to changes in oxygen availability. In the presence of oxygen, HIF is targeted for destruction by an E3 ubiquitin ligase containing the von Hippel-Lindau tumor suppressor protein (pVHL). We found that human pVHL binds to a short HIF-derived peptide when a conserved proline residue at the core of this peptide is hydroxylated. Because proline hydroxylation requires molecular oxygen and Fe(2+), this protein modification may play a key role in mammalian oxygen sensing.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hypoxia in cancer: significance and impact on clinical outcome.

              Hypoxia, a characteristic feature of locally advanced solid tumors, has emerged as a pivotal factor of the tumor (patho-)physiome since it can promote tumor progression and resistance to therapy. Hypoxia represents a "Janus face" in tumor biology because (a) it is associated with restrained proliferation, differentiation, necrosis or apoptosis, and (b) it can also lead to the development of an aggressive phenotype. Independent of standard prognostic factors, such as tumor stage and nodal status, hypoxia has been suggested as an adverse prognostic factor for patient outcome. Studies of tumor hypoxia involving the direct assessment of the oxygenation status have suggested worse disease-free survival for patients with hypoxic cervical cancers or soft tissue sarcomas. In head & neck cancers the studies suggest that hypoxia is prognostic for survival and local control. Technical limitations of the direct O(2) sensing technique have prompted the use of surrogate markers for tumor hypoxia, such as hypoxia-related endogenous proteins (e.g., HIF-1alpha, GLUT-1, CA IX) or exogenous bioreductive drugs. In many - albeit not in all - studies endogenous markers showed prognostic significance for patient outcome. The prognostic relevance of exogenous markers, however, appears to be limited. Noninvasive assessment of hypoxia using imaging techniques can be achieved with PET or SPECT detection of radiolabeled tracers or with MRI techniques (e.g., BOLD). Clinical experience with these methods regarding patient prognosis is so far only limited. In the clinical studies performed up until now, the lack of standardized treatment protocols, inconsistencies of the endpoints characterizing the oxygenation status and methodological differences (e.g., different immunohistochemical staining procedures) may compromise the power of the prognostic parameter used.
                Bookmark

                Author and article information

                Contributors
                +3906-5266-2800 , tiziana.bruno@ifo.gov.it
                mcvalerio@gmail.com
                luca.casadei@uniroma1.it
                francesca.denicola@ifo.gov.it
                frauke.goeman@ifo.gov.it
                pallocca@gmail.com
                valeria.catena@ifo.gov.it
                simona.iezzi@ifo.gov.it
                cristina.sorino@ifo.gov.it
                agata.desantis@ifo.gov.it
                cesare.manetti@uniroma1.it
                giovanni.blandino@ifo.gov.it
                aristide.floridi@gmail.com
                +3906-5266-2800 , maurizio.fanciulli@ifo.gov.it
                Journal
                J Exp Clin Cancer Res
                J. Exp. Clin. Cancer Res
                Journal of Experimental & Clinical Cancer Research : CR
                BioMed Central (London )
                0392-9078
                1756-9966
                18 February 2017
                18 February 2017
                2017
                : 36
                : 32
                Affiliations
                [1 ]ISNI 0000 0004 1760 5276, GRID grid.417520.5, UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, Translational Research Area, , Regina Elena National Cancer Institute, ; Via E. Chianesi 53, 00144 Rome, Italy
                [2 ]GRID grid.7841.a, Department of Chemistry, , “Sapienza” University, ; Rome, Italy
                [3 ]ISNI 0000 0004 1760 5276, GRID grid.417520.5, UOSD Oncogenomic and Epigenetic Unit, , Regina Elena National Cancer Institute, ; Rome, Italy
                Article
                497
                10.1186/s13046-017-0497-1
                5316229
                28214471
                a9a31c2d-b269-4971-a1d5-0ebaf5f3bc48
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 12 January 2017
                : 28 January 2017
                Funding
                Funded by: Associazione italiana ricerca cancro - AIRC
                Award ID: IG15255
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Oncology & Radiotherapy
                che-1/aatf,hypoxia,metabolism,hif-1α,phd3/egln3,siah-2
                Oncology & Radiotherapy
                che-1/aatf, hypoxia, metabolism, hif-1α, phd3/egln3, siah-2

                Comments

                Comment on this article